USP22 and hepatocellular carcinoma: Since growing evidences demonstrate that Sorafenib exerts anti‐tumour effects in hepatocellular carcinoma via inducing ferroptosis,7, 8 we therefore examined several markers of ferroptosis in control and USP22 knockout/knockdown cells to determine whether USP22 knockout/knockdown affects Sorafenib‐induced ferroptosis.